Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 / 抑制剂/激动剂 /
血管生成
蛋白质酪氨酸激酶
/ BTK / Ibrutinib

伊布替尼 /Ibrutinib {[allProObj[0].p_purity_real_show]}

货号：A150396 同义名： 依鲁替尼 / PCI-32765;Imbruvica

Ibrutinib（PCI-32765）是一种选择性、不可逆的Btk抑制剂，IC50为0.5 nM。

Ibrutinib 化学结构 CAS号：936563-96-1
Ibrutinib 化学结构
CAS号：936563-96-1
Ibrutinib 3D分子结构
CAS号：936563-96-1
Ibrutinib 化学结构 CAS号：936563-96-1
Ibrutinib 3D分子结构 CAS号：936563-96-1
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} 		{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Ibrutinib 纯度/质量文件 产品仅供科研

货号：A150396 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Cell Host Microbe, 2024. Ambeed. [ A163338 ]
• Cancer Res., 2024. Ambeed. [ A295334 ]
• J. Pharm. Investig., 2024. Ambeed. [ A221527 , A691302 , A272538 , A187261 ]
• J. Fungi, 2024, 10(11): 751. Ambeed. [ A796919 ]
• JBC, 2024, 107935. Ambeed. [ A194396 ]
更多 >
产品名称 BTK ↓ 其他靶点 纯度
CGI-1746 +++

BTK, IC50: 1.9 nM

 		98%
Spebrutinib ++++

BTK, IC50: <0.5 nM

 		98+%
Acalabrutinib ++

BTK, IC50: 3nM

 		98%
CNX-774 +++

BTK, IC50: <1 nM

 		99%+
Ibrutinib ++++

BTK, IC50: 0.5 nM

 		98%
ONO-4059 analog +

BTK, IC50: 23.9 nM

 		98%
RN486 ++

BTK, IC50: 4 nM

 		99%+
(Z)-LFM-A13 +

BTK, Ki: 1.4 μM

 		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Ibrutinib 生物活性

靶点

  • BTK

    BTK, IC50:0.5 nM
描述 Btk (Bruton tyrosine kinase), a non-receptor tyrosine kinase, is specifically required for BCR signaling which contributes to the initiation and maintenance of B-cell malignancies and autoimmune diseases. Ibrutinib, also called as PCI-32765 or imbruvica, is a potent Btk inhibitor with IC50 of 0.5 nM (measured by 33P filtration binding assay), modestly potent to Blk (IC50= 0.5 nM), Bmx (IC50= 0.8 nM), CSK (IC50= 2.3 nM), FGR (IC50= 2.3 nM), BRK (IC50= 3.3 nM), HCK (IC50= 3.7 nM), less potent to EGFR (IC50= 5.6 nM), Yes (IC50= 6.5 nM), ErbB2 (IC50= 9.4 nM), ITK (IC50= 10.7 nM). Ibrutinib can selectively inhibit B-cell signaling and activation, including inhibition of autophosphorylation of Btk, phosphorylation of Btk's physiological substrate PLCγ and phosphorylation of a further downstream kinase ERK, in DOHH2 cells. Continuous exposure to 10 nM Ibrutinib for 18h completely prevented up-regulation of CD69, the B-cell activation marker. In vivo study shows that Btk inhibition by Ibrutinib is efficacious for autoimmune disease animal model. Oral treatment daily for 11 days with 12.5 mg/kg of Ibrutinib can inhibit collagen-induced arthritis in mice[1]. Up to now, Ibrutinib is approved to the treatment of mantle cell lymphoma, chronic lymphocytic leukemia, Waldenstrom's macroglobulinemia, small lymphocytic lymphoma, marginal zone lymphoma, and chronic graft versus host disease[2].
作用机制 Ibrutinib can bind covalently to a cysteine residue (Cys-481) in the active site, leading to potent and irreversible inhibition of Btk enzymatic activity[3]. Notice: BMX, EGFR, ErbB2, ITK, JAK3,AK3 and TEC is the kinase that contains a cysteine residue aligning with Cys-481 same as Btk, resulting in the binding with Ibrutinib[1].

Ibrutinib 细胞研究

细胞系 浓度 检测类型 检测时间 活动说明 数据源
human DOHH2 cells Cytotoxic assay 72 h Cytotoxicity against human DOHH2 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50=0.41 μM. 24915291
human Pfeiffer cells Function assay 72 h Cytotoxicity against human Pfeiffer cells assessed as growth inhibition after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50=2 nM. 24915291
human Ramos cells Function assay 1 h Inhibition of Btk in human Ramos cells assessed as inhibition of PLC-gamma2 phosphorylation at Tyr1217 after 1 hr by Western blot analysis, IC50=14 nM. 24915291
human Rec1 cells 2.5 μM Function assay 6 h Inhibition of Lyn phosphorylation in human Rec1 cells at 2.5 uM incubated for 6 hrs by Western blotting method 25222877

Ibrutinib 动物研究

Dose Mice[3]: min = 2.5 mg/kg, max = 25 mg/kg
Administration p.o.

Ibrutinib 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02824029 Classical Hodgkin Lymphoma ... 展开 >> Recurrent Hodgkin Lymphoma Refractory Hodgkin Lymphoma 收起 << Phase 2 Recruiting February 2019 United States, Michigan ... 展开 >> Wayne State University/Karmanos Cancer Institute Recruiting Detroit, Michigan, United States, 48201 Contact: Radhakrishnan Ramchandren    313-576-8739       Principal Investigator: Radhakrishnan Ramchandren, M.D.          Sub-Investigator: Divaya Bhutani, M.D.          Sub-Investigator: Jay Yang, M.D.          Sub-Investigator: Jeffrey Zonder, M.D.          Sub-Investigator: Charles Schiffer, M.D.          Sub-Investigator: Abhinav Deol, M.D.          United States, Texas M D Anderson Cancer Center Not yet recruiting Houston, Texas, United States, 77030 Contact: Michelle A. Fanale    713-792-2860    mfanale@mdanderson.org    Principal Investigator: Michelle A. Fanale 收起 <<
NCT03021460 Metastatic Melanoma ... 展开 >> Stage III Skin Melanoma Stage IIIA Skin Melanoma Stage IIIB Skin Melanoma Stage IIIC Skin Melanoma Stage IV Skin Melanoma 收起 << Phase 2 Recruiting February 1, 2021 United States, Minnesota ... 展开 >> Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Clinical Trials Referral Office    855-776-0015       Principal Investigator: Matthew S. Block 收起 <<
NCT02899078 Metastatic Renal Cell Cancer ... 展开 >> Stage IV Renal Cell Cancer 收起 << Phase 1 Phase 2 Recruiting May 2020 United States, California ... 展开 >> University of California Davis Comprehensive Cancer Center Recruiting Sacramento, California, United States, 95817 Contact: Primo N. Lara, M.D.    916-734-3771    pnlara@ucdavis.edu    Principal Investigator: Primo N. Lara, M.D.          Sub-Investigator: Chong-Xian Pan, M.D., Ph.D. 收起 <<

Ibrutinib 参考文献

[1]Honigberg LA, Smith AM, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80.

[2]Pan Z, Scheerens H, et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem. 2007 Jan;2(1):58-61.

Ibrutinib 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.27mL

0.45mL

0.23mL

11.35mL

2.27mL

1.14mL

22.70mL

4.54mL

2.27mL

Ibrutinib 技术信息

CAS号936563-96-1
分子式C25H24N6O2
分子量 440.497
别名 依鲁替尼 ;PCI-32765;Imbruvica;PCI32765, PCI-32765, PCI 32765, Ibrutinib, Imbruvica
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Keep in dark place,Inert atmosphere,2-8°C
溶解度

DMSO: 105 mg/mL(238.37 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方

IP 2% DMSO+2% Tween80+40% PEG300+water 12 mg/mL clear

PO 0.5% CMC-Na 35 mg/mL suspension

Tags: Ibrutinib | PCI-32765;Imbruvica;PCI32765, PCI-32765, PCI 32765, Ibrutinib, Imbruvica | 依鲁替尼 | BTK | AmBeed-信号通路专用抑制剂 | Ibrutinib 纯度/质量文件 | Ibrutinib 亚型比较 | Ibrutinib 生物活性 | Ibrutinib 细胞研究 | Ibrutinib 动物研究 | Ibrutinib 临床数据 | Ibrutinib 参考文献 | Ibrutinib 实验方案 | Ibrutinib 技术信息

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 Ambeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z